Literature DB >> 14538051

Kinetics of 3'-deoxy-3'-[F-18]fluorothymidine uptake and retention in dogs.

Anthony F Shields1, John R Grierson, Otto Muzik, Joseph C Stayanoff, Jawana M Lawhorn-Crews, Joyce E Obradovich, Thomas J Mangner.   

Abstract

We have developed 3'-deoxy-3'-[F-18] fluorothymidine ([F-18]FLT) as an agent to image cellular proliferation with PET. Recent work has demonstrated that [F-18]FLT is stable to degradation and produces high contrast images of proliferating tissues and tumors. To increase our understanding for the use of this agent we have explored the kinetics of [F-18]FLT clearance from the blood and uptake into tissues in normal and tumor bearing dogs. The results indicate that [F-18]FLT is readily modeled in canines with a three-compartment model, with parameter k(3) representing phosphorylation by thymidine kinase. During the first 60 minutes, little loss was measured from the phosphorylated compartment, therefore parameter k(4) could not be differentiated from zero. The extraction of marrow from normal dogs was consistent with this model and demonstrated retention of phosphorylated [F-18]FLT. It is concluded that [F-18]FLT produces images of the DNA synthetic pathway by phosphorylation via thymidine kinase. This pathway can be readily modeled using a three-compartment model.

Entities:  

Year:  2002        PMID: 14538051     DOI: 10.1016/s1095-0397(01)00070-x

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  20 in total

Review 1.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

2.  A simplified analysis of [18F]3'-deoxy-3'-fluorothymidine metabolism and retention.

Authors:  Anthony F Shields; David A Briston; Samatha Chandupatla; Kirk A Douglas; Jawana Lawhorn-Crews; Jerry M Collins; Thomas J Mangner; Lance K Heilbrun; Otto Muzik
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-01       Impact factor: 9.236

Review 3.  Brain tumors.

Authors:  Karl Herholz; Karl-Josef Langen; Christiaan Schiepers; James M Mountz
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

4.  Improved detection and measurement of low levels of [18F]fluoride metabolized from [18F]-labeled pyrimidine nucleoside analogues in biological samples.

Authors:  Vincenzo Paolillo; Hsin Hsien Yeh; Uday Mukhopadhyay; Juri G Gelovani; Mian M Alauddin
Journal:  Nucl Med Biol       Date:  2011-07-08       Impact factor: 2.408

5.  Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging.

Authors:  Matt Vanderhoek; Mark B Juckett; Scott B Perlman; Robert J Nickles; Robert Jeraj
Journal:  Leuk Res       Date:  2010-09-15       Impact factor: 3.156

6.  Using Radiolabeled 3'-Deoxy-3'-18F-Fluorothymidine with PET to Monitor the Effect of Dexamethasone on Non-Small Cell Lung Cancer.

Authors:  Christopher I McHugh; Monica R Thipparthi; Jawana M Lawhorn-Crews; Lisa Polin; Shirish Gadgeel; Janice Akoury; Thomas J Mangner; Kirk A Douglas; Jing Li; Manohar Ratnam; Anthony F Shields
Journal:  J Nucl Med       Date:  2018-04-19       Impact factor: 10.057

7.  PET/CT in prostate cancer: non-choline radiopharmaceuticals.

Authors:  P Castellucci; H Jadvar
Journal:  Q J Nucl Med Mol Imaging       Date:  2012-08       Impact factor: 2.346

8.  [18F]FLT PET for diagnosis and staging of thoracic tumours.

Authors:  Helmut Dittmann; Bernhard Matthias Dohmen; Frank Paulsen; Kai Eichhorn; Susanne Martina Eschmann; Marius Horger; Manfred Wehrmann; Hans Juergen Machulla; Roland Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-26       Impact factor: 9.236

Review 9.  The role of DNA synthesis imaging in cancer in the era of targeted therapeutics.

Authors:  Sridhar Nimmagadda; Anthony F Shields
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

10.  Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer.

Authors:  D Visvikis; D Francis; R Mulligan; D C Costa; I Croasdale; S K Luthra; I Taylor; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.